Cargando…

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients included in various treatment trials for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, S A, Ganesan, R, Hiller, L, Murray, P G, El-Magraby, M M, Young, L, James, N D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377165/
https://www.ncbi.nlm.nih.gov/pubmed/12592374
http://dx.doi.org/10.1038/sj.bjc.6600765
_version_ 1782154792359952384
author Hussain, S A
Ganesan, R
Hiller, L
Murray, P G
El-Magraby, M M
Young, L
James, N D
author_facet Hussain, S A
Ganesan, R
Hiller, L
Murray, P G
El-Magraby, M M
Young, L
James, N D
author_sort Hussain, S A
collection PubMed
description The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients included in various treatment trials for transitional cell carcinoma (TCC) of the bladder. Data were collected on 94 patients who first presented with either invasive or superficial bladder cancer. Median follow-up for alive patients was 83 months (m) (range 12–195 m). Median survival was 80 m (95% CI=56–128 m). Median survivals for the various markers were as follows: BAX-positive patients 110 m vs BAX-negative patients18 m (P=0.0002); CD40L-positive patients 95 m vs CD40L-negative patients 45 m (P=0.04); BCL2-positive patients 44 m and BCL2-negative patients 74 m, (P=0.64); CD40-positive patients 110 m and CD40 negative patients 45 m (P=0.12); and P53 positive patients 80 m and P53 negative patients 45 m (P=0.58). In conclusion, it was seen that overexpressions of BAX and CD40L are prognostic of better survival in TCC of the bladder. Our results also raise the possibility of the future development of CD40- and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival.
format Text
id pubmed-2377165
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23771652009-09-10 Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder Hussain, S A Ganesan, R Hiller, L Murray, P G El-Magraby, M M Young, L James, N D Br J Cancer Genetics and Genomics The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients included in various treatment trials for transitional cell carcinoma (TCC) of the bladder. Data were collected on 94 patients who first presented with either invasive or superficial bladder cancer. Median follow-up for alive patients was 83 months (m) (range 12–195 m). Median survival was 80 m (95% CI=56–128 m). Median survivals for the various markers were as follows: BAX-positive patients 110 m vs BAX-negative patients18 m (P=0.0002); CD40L-positive patients 95 m vs CD40L-negative patients 45 m (P=0.04); BCL2-positive patients 44 m and BCL2-negative patients 74 m, (P=0.64); CD40-positive patients 110 m and CD40 negative patients 45 m (P=0.12); and P53 positive patients 80 m and P53 negative patients 45 m (P=0.58). In conclusion, it was seen that overexpressions of BAX and CD40L are prognostic of better survival in TCC of the bladder. Our results also raise the possibility of the future development of CD40- and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and antiapoptotic markers to overall survival. Nature Publishing Group 2003-02-24 2003-02-18 /pmc/articles/PMC2377165/ /pubmed/12592374 http://dx.doi.org/10.1038/sj.bjc.6600765 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Genetics and Genomics
Hussain, S A
Ganesan, R
Hiller, L
Murray, P G
El-Magraby, M M
Young, L
James, N D
Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title_full Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title_fullStr Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title_full_unstemmed Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title_short Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder
title_sort proapoptotic genes bax and cd40l are predictors of survival in transitional cell carcinoma of the bladder
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377165/
https://www.ncbi.nlm.nih.gov/pubmed/12592374
http://dx.doi.org/10.1038/sj.bjc.6600765
work_keys_str_mv AT hussainsa proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT ganesanr proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT hillerl proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT murraypg proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT elmagrabymm proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT youngl proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder
AT jamesnd proapoptoticgenesbaxandcd40larepredictorsofsurvivalintransitionalcellcarcinomaofthebladder